ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

penpulimab

Also written as “AK105”, “Penpulimab” and “Penpulimab injection”.

Its studies are mostly in Carcinoma, Hepatocellular · Nasopharyngeal Carcinoma · Carcinoma, Non-Small-Cell Lung · Hodgkin Disease · Esophageal Squamous Cell Carcinoma, led by 2 companies.

Drug pagePenpulimab: every studyAll 65 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Apr 10, 202027 company-led studies, 9 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical187 open or runningphase 3since Apr 10, 2020Dec 17, 2019Dec 2026phase 3 · NCT04344158
Akesoits history only92 open or runningphase 3since Mar 6, 2019Nov 21, 2017none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sino Biopharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Dec 17, 2019.

  1. Apr 10, 2020Phase 3 study in Advanced Hepatocellular Carcinoma (HCC)NCT04344158 · 648 enrolled · China
  2. May 9, 2020Phase 3 study in Advanced Gastric and Gastro-oesophageal Junction AdenocarcinomaNCT04385550 · 528 enrolled · China
  3. Jun 9, 2020Named penpulimabINNProposed as its International Nonproprietary Name in WHO's List 123 · before, AK105
  4. Sep 24, 2021Phase 2 study in Unresectable Metastatic Colorectal CancerNCT05068206 · 120 enrolled · China
  5. Apr 12, 2022Phase 1 study in Advanced CancersNCT05333276 · 7 enrolled · China
  6. May 16, 2022Phase 2 study in LymphomaNCT05400876 · 92 enrolled · China
  7. Sep 27, 2022Phase 2 study in Nasopharyngeal CarcinomaNCT05563480 · 47 enrolled · China
  8. Apr 18, 2023Phase 2 study in Advanced Esophageal Squamous Cell CarcinomaNCT05834543 · 34 enrolled · China
  9. May 15, 2023Phase 3 study in Carcinoma, HepatocellularNCT05862337 · 480 planned · China
  10. May 31, 2023Phase 1 study in Advanced CancerNCT05894421 · 92 planned · China
  11. Jul 27, 2023Phase 1 study in Advanced Hepatocellular CarcinomaNCT05975645 · 29 enrolled · China
  12. Mar 1, 20242 phase 1 studiesNCT06297642, NCT06320080
  13. Jul 8, 2024Phase 2 study in SarcomaNCT06500091 · 54 planned · China
  14. Jan 6, 2025Phase 2 study in Gastroesophageal AdenocarcinomaNCT06767800 · 204 planned · China
  15. Feb 9, 2025Phase 2 study in Advanced Solid TumorNCT06825494 · 194 planned · China

Ahead

  1. Dec 2026Primary completion: phase 3 study in Advanced Hepatocellular Carcinoma (HCC)NCT04344158

TargetBeta

PDCD1 →read by rule
“A monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), ”NCIt, by rule
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

All 18 Sino Biopharmaceutical leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06825494Advanced Solid Tumor · China2RecruitingMar 2026194
NCT06767800Gastroesophageal Adenocarcinoma · China2RecruitingSep 2026204
NCT06500091Sarcoma · China2Not yet recruitingJun 202654
NCT06320080Advanced Hepatocellular Carcinoma · China1TerminatedNov 3, 202522
NCT06297642Advanced Malignant Neoplasm · China1TerminatedJul 31, 20243
NCT05975645Advanced Hepatocellular Carcinoma · China1TerminatedJun 4, 202529
NCT05894421Advanced Cancer · China1RecruitingJan 202592
NCT05862337Carcinoma, Hepatocellular · China3RecruitingAug 2024480
NCT05834543Advanced Esophageal Squamous Cell Carcinoma · China2TerminatedOct 23, 202434
NCT05563480Nasopharyngeal Carcinoma · China2CompletedMay 28, 202547
NCT05400876Lymphoma · China2UNKNOWNMay 202392
NCT05333276Advanced Cancers · China1Active, not recruitingDec 20237
NCT05068206Unresectable Metastatic Colorectal Cancer · China2UNKNOWNDec 2023120
NCT04385550Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma · China3UNKNOWNOct 31, 2023528
NCT04344158Advanced Hepatocellular Carcinoma (HCC) · China3Active, not recruitingDec 2026648
NCT04291248MSI-H or dMMR Advanced Solid Tumors · China2UNKNOWNDec 2022138
NCT04207463Digestive System Neoplasms · China2UNKNOWNDec 31, 2020150
NCT04203719Advanced Head, Neck and Chest Cancer · China2UNKNOWNDec 31, 2020140

How it is read

Names in the registry

  • “AK105”, 9 entries
  • “Penpulimab”, 3 entries
  • “Penpulimab injection”, 2 entries
  • “AK105 injection”, 2 entries
  • “TQB2618 injection; Penpulimab injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.